US › Healthcare

Revelation Biosciences Inc (REVB)

US · Healthcare · Biotechnology

$0.48-36.35%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-3.3M

EPS

$-0.87

EPS estimate

$-0.83

EPS came in at -0.87 against a street estimate of -0.83 — a miss of 4.8%.

Key statistics

Market cap

$2.9M

P/E

0.2

Forward P/E

0.9

P/B

0.39

Book value

$2.58

EPS (TTM)

$4.60

52-week high

$5.60

52-week low

$0.71

50-day MA

$0.97

200-day MA

$1.36

Beta

-0.06

Analyst view

Analysts rate Revelation Biosciences Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $17.75.

Shareholding

Insiders

12.34%

Institutions

12.89%

Largest institutional holders

Fund	Stake
Sabby Management LLC	5.29%
Citadel Advisors Llc	0.97%
Geode Capital Management, LLC	0.43%
HRT FINANCIAL LLC	0.43%
Vanguard Fiduciary Trust Co	0.33%
Tower Research Capital LLC	0.16%
Royal Bank of Canada	0.02%
SBI Securities Co Ltd	0.01%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Revelation Biosciences Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.